A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes.
D000328:Adult; D002208:Caproates / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000097:blood / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011581:Psychological Tests; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D002208:Caproates; D003692:Delayed-Action Preparations; D005464:Fluorobenzenes; D006993:Hypnotics and Sedatives; D010880:Piperidines; D013141:Spiro Compounds; D005476:Fluphenazine